Department of Central Research Laboratories, Sysmex Corporation, Takatsukadai, Nishi-ku, Kobe, Japan.
PLoS One. 2020 Aug 13;15(8):e0237506. doi: 10.1371/journal.pone.0237506. eCollection 2020.
Circulating tumor cells (CTCs) invade blood vessels in solid tumors and promote metastases by circulating in the blood. CTCs are thus recognized as targets for liquid biopsy and can provide useful information for design of treatments. This diagnostic approach must consider not only the number of CTCs but also their molecular and genetic characteristics. For this purpose, use of devices that enrich CTCs independent of these characteristics and detectors that recognize various CTC characteristics is essential. In the present study, we developed a CTC detection system comprising ClearCell FX and ImageStream Mark II. We clarified the analytical performance of this system by evaluating recovery rate, lower limits of detection, and linearity. These parameters are critical for detecting rare cells, such as CTCs. We tested these parameters using three cell lines with different expression levels of the epithelial marker-epithelial cell adhesion molecule (EpCAM) and spiked these cells into whole-blood samples from healthy donors. The average recovery rate and lower limit of detection were approximately 40% and five cells/7.5 mL of whole blood, respectively. High linearity was observed for all evaluated samples. We also evaluated the ability of the system to distinguish between normal and abnormal cells based on protein expression levels and gene amplification and found that the system can identify abnormal cells using these characteristics. The CTC detection system thus displays the ability to distinguish specific characteristics of CTC, thereby providing valuable information for cancer treatment.
循环肿瘤细胞 (CTC) 通过在血液中循环而从实体瘤中侵入血管并促进转移。因此,CTC 被认为是液体活检的靶标,并能为治疗方案的设计提供有用的信息。这种诊断方法不仅必须考虑 CTC 的数量,还必须考虑其分子和遗传特征。为此,必须使用独立于这些特征富集 CTC 的设备和识别各种 CTC 特征的探测器。在本研究中,我们开发了一种包含 ClearCell FX 和 ImageStream Mark II 的 CTC 检测系统。我们通过评估回收率、检测下限和线性度来阐明该系统的分析性能。这些参数对于检测稀有细胞(如 CTC)至关重要。我们使用三种上皮标志物-上皮细胞黏附分子 (EpCAM) 表达水平不同的细胞系测试了这些参数,并将这些细胞系混入来自健康供体的全血样本中。平均回收率和检测下限分别约为 40%和每 7.5 毫升全血 5 个细胞。所有评估的样本均表现出高度的线性。我们还评估了该系统基于蛋白表达水平和基因扩增区分正常和异常细胞的能力,发现该系统可以使用这些特征识别异常细胞。因此,CTC 检测系统具有区分 CTC 特定特征的能力,从而为癌症治疗提供有价值的信息。